Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of H3B-6527. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 18/20 | 0.94 |
| ▸ | FGFR4 known ✓ | P22455 | 8/20 | 0.94 |
| ▸ | FGFR2 known ✓ | P21802 | 4/20 | 0.94 |
| ▸ | FGFR3 known ✓ | P22607 | 4/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| H3B-6527 SCHEMBL30070398 | 1.00 | FGFR1 (0.94) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30274661 | 0.97 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL16659467 | 0.97 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL29412748 | 0.97 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30070526 | 0.96 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL18153616 | 0.96 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL30070306 | 0.96 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| H3B-6527 SCHEMBL18153614 | 0.96 | FGFR1 (0.99) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16659479 | 0.94 | FGFR4 (1.00) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16665254 | 0.93 | FGFR1 (0.92) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107660200-B | Crystalline FGFR4 inhibitor compounds and uses thereof | 卫材R&D管理有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3283465-B1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MAN CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| EP-3283465-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168331-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.